| Name | Title | Contact Details |
|---|
The Wound Pros, LLC is a physician-owned Medicare Part B supplier of the industry’s most advanced wound care dressings. As a bonus, Wound Pros offers excellent clinical expertise which gives our patients the best opportunity to heal efficiently. Our vision is to change the way the world treats and manages non-healing wounds. Chronic non-healing wounds can compromise the quality of life for those living in long-term care facilities. The longer a wound remains open or unhealed, the greater the chance of unwanted complications such as infection, hospitalisation, and even amputation. At The Wound Pros, we are dedicated to meeting this challenge head-on with our "Hi-Tech Hi-Touch Approach” to wound care management. Our vision is to change the way the world treats and manages chronic non-healing wounds with better data, better decision making and better documentation.
were innovating medical transportation & changing the standards of ambulance service to improve the lives of emts, patients & healthcare providers
IBC USA Conferences is a Westborough, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
National Medical Products is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.